Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability
Nishida, Y
Multiple sclerosis-like syndrome in a woman heterozygous for adrenoleukodystrophy
Untreated and BSO-treated HeLa cells were infected with PV1-wt (moi 10) and metabolically labeled with 35 S-Translabel from 46 hr post-infection

Major Ingredients Water(Aqua), Ascorbic Acid (150,000ppm), Dicaprylyl Carbonate, Propanediol, Dipropylene Glycol, Butylene Glycol, Phenyl Trimethicone, Diisostearyl Malate, Hydrogenated Poly(C6-14 Olefin), Glyceryl Stearate, 1,2-Hexanediol, Sodium Hydroxide, C12-14 Alketh-12, PEG-100 Stearate, Vinyl Dimethicone, Bisabolol (5,000ppm), Polyglyceryl-3 Distearate, Sodium Stearoyl Glutamate, Polyacrylate Crosspolymer-6, Hydrolyzed Sclerotium Gum, Allantoin, Tocopherol (1,001ppm), Xanthan Gum, Sodium Hyaluronate, Pullulan, Panthenol (1,000ppm), Ethylhexylglycerin, Glyceryl Stearate Citrate, Glutathione (500ppm), Asparagus Officinalis Extract (500ppm), Citrus Aurantium Dulcis (Orange) Flower Oil, Litsea Cubeba Fruit Oil, Adenosine, Citrus Paradisi (Grapefruit) Peel Oil, Citrus Aurantium Bergamia (Bergamot) Fruit Oil, Disodium EDTA, Beta-Glucan (200ppm), Mentha Viridis (Spearmint) Leaf Oil, Barosma Betulina Leaf Extract, Glycerin, Sorbitol, Helianthus Annuus (Sunflower) Seed Oil, Sucrose Stearate, Caprylic/Capric Triglyceride, Beta-Carotene, Ferulic Acid (1ppm), Hesperidin (0.001ppm), Ergothioneine (0.001ppm), Limonene, Linalool, Citral Ingredients subject to change at manufacturer's discretion

BPC 157s endothelial effects and its function as a bypassing key (Sikiric et al., 2018) are strongly supported by its interaction with the nitric oxide (NO) system (for a review, see Sikiric et al., 2014)